Andrew Vick, Ph.D.

Head of Toxicology, Drug Disposition, and PKPD
Attralus, Inc.
San Francisco, California

Andy has over 24 years of experience working within the biotechnology and pharmaceutical industry on both the innovator and supplier sides in the fields of toxicology, nonclinical and clinical pharmacology, and drug disposition. Currently, Andy is responsible for the nonclinical safety, drug disposition, and PKPKD characterization of Attralus’s therapeutic assets. Previously, Andy has served in executive roles with Charles River Laboratories, WIL Research Laboratories (acquired by CRL), Seventh Wave Laboratories, as well as served in key scientific roles at Eli Lilly and Company and Biogen. Andy earned his BS in Zoology and PhD in Pharmaceutical Chemistry from The Ohio State University. He has continued his support of the University through service on the Dean’s Corporate Council for the College of Pharmacy, and he serves the Division of Pharmaceutical Chemistry as an Adjunct Professor. Andy also serves in the role of Immediate Past President for AAPS.

Disclosure information not submitted.

Presentation(s):

• Special Poster Collection

  Tuesday, October 18, 2022
  10:30 AM – 11:30 AM ET